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Abstract. Background: Neuroendocrine neoplasms include
a heterogeneous group of malignant tumors. Primary
neuroendocrine tumors in the genitourinary tract are rare,
comprising approximately 1-2% of genitourinary
malignancies. Materials and Methods: An extensive search
was performed for publications between 2000 and 2018
regarding neuroendocrine tumors of the genitourinary tract.
Epidemiological, clinical, histopathological, prognostic and
therapeutic data were evaluated. Results: Neuroendocrine
tumors of the kidneys are exceedingly rare, mostly well-
differentiated. 0.5-1% of all primary bladder malignancies
are small cell neuroendocrine carcinomas. Characteristically,
prostatic adenocarcinoma with neuroendocrine differentiation
occurs in androgen receptor-independent/castrate-resistant
cancer. Small cell and large cell neuroendocrine carcinomas
are the most aggressive tumors in each location. Conclusion:
Due to the rarity and poor prognosis of these tumors, proper
pathological diagnosis and early therapy are important.
Therapeutic guidelines are not available. Surgery,
radiotherapy and/or chemotherapy are possible treatment
options; somatostatin analogs are used as standard therapy
in case of well-differentiated neuroendocrine tumors.
Neuroendocrine neoplasms (NENs) make up a heterogeneous
group of malignant tumors with distinct histological features,
clinical behavior, and patient outcome. NENs can arise virtually
in any organ system, although 85% of NENs affect the
gastrointestinal (GI) tract and the lungs. Primary neuroendocrine
tumors of the genitourinary (GU) tract are rare, accounting for
less than 1-2% of GU malignancies (1, 2). Primary
neuroendocrine tumors may develop anywhere in the GU tract;
they are most frequently localized in the prostate, but the
involvement of the kidneys, urinary bladder, testes, ovaries, and
the uterus results in challenging diagnostic and therapeutic
dilemmas. Otherwise, the GU tract is a potential site for
metastases from other primary neuroendocrine tumors (3). On
the basis of the 2016 World Health Organization (WHO)
Classification of Tumors of Urinary System and Male Genital
Organ classification system, they can be described as well-
differentiated neuroendocrine tumors (NET), large cell
neuroendocrine carcinoma, small cell neuroendocrine carcinoma,
and paraganglioma. The exact classification depends on the site
of the origin (Table I) (4). Within this systematic review, the
incidence, the pathological features, and prognostic data of
NENs of the kidney, urinary bladder, and prostate are discussed
together with an emphasis on the main differential diagnostic and
therapeutic considerations. The various phenotypes are discussed
below separately per organ. The morphological categorization is
described by the WHO classification (Table I) (4).
Materials and Methods
PubMed database and clinical trials were searched with publication
dates between January 2000 and January 2018. The keywords and the
associated results include: The key word ’neuroendocrine genitourinary
tumor’, gave 656 results, out of which 181 were review papers, 358
pathology studies, and 117 case reports. The keyword ’neuroendocrine
genitourinary tumor therapy’, gave 314 papers. The search was
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extended separately for the following organs. For ’neuroendocrine
prostate tumor’, 1130 papers were identified, and for ’neuroendocrine
prostate carcinoma’ 594 papers. 301 results were identified for the
keyword ’neuroendocrine prostate tumor carcinoma therapy’, and 211
for ’neuroendocrine urinary bladder tumor’, 172 for ’neuroendocrine
urinary bladder carcinoma’, and 87 for ’neuroendocrine urinary bladder
tumor carcinoma therapy’. For ’neuroendocrine kidney tumor’ 570, for
’neuroendocrine kidney carcinoma’ 449, and for ’neuroendocrine
kidney tumor carcinoma therapy’ 154 papers were found. Only
publications in English language were included, and also English
language abstracts even if the whole paper was written in another
language. Basically, reviews papers were excluded unless they were
published after the year 2000, and contained data essential for this
review. A comprehensive summary regarding the prognosis and
potential therapy in case of urological NETs is presented.
Results
Neuroendocrine tumors of the kidney
Neuroendocrine tumors of the kidney are exceedingly rare,
and they are classified into well-differentiated tumors, small
cell carcinomas and large cell carcinomas (5).
Well-differentiated NET of the kidney. Primary kidney well-
differentiated neuroendocrine tumors (formerly carcinoids) are
rare. Only about 90 cases are reported in the literature (6).
Interestingly, a significant proportion of kidney NETs were
associated with horseshoe kidney (18-26% of the patients) (7,
8). There is no gender predilection. The mean age of the
patients was 49 years, and approximately 25-50% of the cases
were discovered accidentally, and the remaining patients
presented with symptoms similar to the ones caused by renal
cell carcinoma (RCC), such as pain in the pelvic region, weight
loss, fever, palpable mass, and hematuria (3). Carcinoid
syndrome is infrequent, and it is presented only in 10-15% of
patients with the following symptoms: flush, diarrhea, and
generalized edema (9). Radiologically, neither the CT nor the
MRI scan can distinguish this tumor from renal cell carcinoma.
Somatostatin receptor scintigraphy with octreotide has a high
sensitivity for the small and clinically silent renal NETs, and it
also has an important role in staging, follow-up, and
surveillance of the disease (9, 10). Macroscopically, well-
differentiated renal tumors are solitary and well-circumscribed,
occasionally with a pseudocapsule. Focal hemorrhage,
calcification, cystic changes, and tumor cell necrosis are
uncommon (11). The histogenesis of renal NETs are yet
unknown. The renal pelvis contains neuroendocrine cells, but
not the renal parenchyma. The most popular and acceptable
hypothesis is that renal NETs differentiate from
neuroendocrine-committed, primitive totipotential cell lines
(12). Histologically, polygonal tumor cells with granular
amphophilic to eosinophilic cytoplasm can be observed
forming vascularized trabeculae or nests. The nuclei are oval-
shaped with the typical “salt and pepper” chromatin and
minimal pleiomorphism (13). Immunohistochemically, these
tumors demonstrate diffuse chromogranin A, synaptophysin,
CD56, and cytokeratin labeling (12, 13). In support, no
admixture of renal NET and clear cell RCC within the same
tumor has been documented; only one case of synchronous
renal NET and contralateral multilocular cystic renal neoplasm
of low malignant potential has been recorded (12). The
prognosis is controversial; some patients survive for only 6
months, some others for many years, even with metastases
(14). Renal NET is a slow-growing tumor; patients show a
prolonged clinical course, even when they have a metastatic
disease that indicates the indolent behavior of renal NETs (13).
The first choice of therapeutic management for the localized
and even for the metastatic well-differentiated tumors could be
surgical resection (5, 15) because these tumors are
chemoresistant (12). The prognostic and therapeutic details are
presented Table II (10, 13, 16-19).
Small cell neuroendocrine carcinoma of the kidney. Renal
small cell neuroendocrine carcinomas (SCNEC) are rare, the
approximate number of the reported cases is 50 (6, 20-22).
These tumors resemble the small cell carcinoma of the lungs.
In renal small cell neuroendocrine carcinoma, the mean age of
the patients is 59 years; there is no gender predilection, and the
left to right side ratio is 1:1.5. The clinical symptoms are
abdominal pain, macroscopic hematuria, and weight loss.
Macroscopically, these are large tumors with a range from 100-
230 mm, and usually infiltrate the entire kidney (20). The cut
surface is soft, whitish, gritty, and necrotic with a solid growth.
Infiltration of the renal sinus, renal vein, and perirenal tissue is
frequent (21). Microscopically, the tumor consists of poorly
differentiated small, round cells that compose sheets and nests.
Mitoses, vascular tumor emboli, and extensive necrosis are
common (13). The tumor cells show dot-like cytoplasm
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Table I. World Health Organization (WHO) histological classification of neuroendocrine neoplasms of the genitourinary tract in adults (4).
Kidney                                                                                       Urinary Bladder                                                                    Prostate
Well-differentiated neuroendocrine tumor          Well-differentiated neuroendocrine tumor          Adenocarcinoma with neuroendocrine differentiation
Small cell neuroendocrine carcinoma                    Small cell neuroendocrine carcinoma                       Well-differentiated neuroendocrine tumor
Large cell neuroendocrine carcinoma                    Large cell neuroendocrine carcinoma                           Small cell neuroendocrine carcinoma
Paraganglioma                                                                            Paraganglioma                                             Large cell neuroendocrine carcinoma
staining with cytokeratin, and they are variably positive for
chromogranin A, synaptopthysin, CD56, and NSE. As seen in
the bladder, primary renal SCNEC can coexist with in situ
and/or papillary urothelial carcinoma, squamous cell
carcinoma, or adenocarcinoma (23). They are highly aggressive
tumors, and they are associated with poor prognosis; the
median survival is less than 1 year (13, 24).
Large cell neuroendocrine carcinoma of the kidney. Renal
large cell neuroendocrine carcinoma (LCNEC) is an
extremely rare form of cancer with fewer than 10 cases in
the literature (2, 6, 25-27). There is no gender predilection,
and the peak age of incidence is between 50 and 60 years.
Most patients present in an advanced stage; the main
symptoms and signs are pain in the flank, palpable mass,
hydronephrosis, and hematuria, and in some cases, the
symptoms and signs are induced by the distant metastases
(2). Grossly, renal LCNECs have a solid cut surface with
necrosis, and the extrarenal extension is common (2, 25).
The tumor cells are large with abundant cytoplasm, vesicular
chromatin, and prominent nucleoli. There is a brisk mitotic
rate, usually more than 10 per high power field (2). For
establishing the diagnosis, at least focal positivity of the NE
markers is essential (6). The diagnosis can be mistaken for
high-grade renal cell carcinoma or urothelial carcinoma. The
clinical prognosis of these carcinomas is very poor (2). There
is no indication of systematic therapy for renal SCNEC and
LCNEC. Surgery, platinum-based chemotherapy, and
radiotherapy could be an effective multimodal management
(27). See Table II for particular prognostic and therapeutic
data about SCNEC and LCNEC (6, 13, 24, 27-31).
Neuroendocrine tumors of the urinary bladder
Neuroendocrine tumors are very rare in this site, and they can
be classified as well-differentiated tumors, SCNEC, and
LCNEC.
Well-differentiated neuroendocrine tumors of the urinary
bladder. Well-differentiated neuroendocrine tumors of the
urinary bladder (previously called carcinoids) are extremely
rare; there are, approximately, only 25 reported cases in the
literature. These tumors usually develop in elderly male
patients (mean age: 56 years). Symptoms of the disease are
the following: hematuria and irritating voiding difficulties.
No association with carcinoid syndrome has been reported
in the literature (32, 33). These tumors are usually
discovered accidentally (34). Cystoscopy may reveal
polypoid structures with submucosal infiltration 3 to 30 mm
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Table II. Neuroendocrine tumors of the kidney: prognostic and therapeutic data from current references.
                                                                   Prognosis                                  References                            Potential therapy                              References
Kidney
  Well-diff. NET                Indolent behavior in horseshoe kidney         Motta et al.      Ovarian and hepatic metastases, one year       Gedaly et al.
                                                                                                                      2004 (16)         after thecomplete surgery (hysterectomy,          2008 (17)
                                                                                                                                               nephrectomy, hepatectomy) no recurrence
                                           45% of cases present with perirenal fat       Romero et al.      Sunitinib in vascular endothelial growth         Finley et al.
                                          and renal vein infiltration, in 50-60% of         2006 (10)                   factor and hypoxia-inducible                    2011 (18)
                                          patients occured paraaortic lymph node,                                                  factor 2 positive cases
                                                 lung, liver and bone metastases
                                             High metastatic rate: age >40 years,         Mazzucchelli              OS was 9 months after radical                Inagaki et al.
                                                       tumors >4 cm, T3 stage,                          et al.                             nephrectomy, no local                          2013 (19)
                                                        mitotic rate >1/10 HPF                        2009 (13)                      recurrence, no metastasis
  SCNEC and LCNEC                  75% of the patients died                     Lane et al.                    Small cell neuroendocrine                     Piedra Lara 
                                                              within one year                               2007 (6)                 carcinoma occured 4 years after                     et al.
                                                                                                                                                         surgery with local recurrence                    2003 (29)
                                             Poor prognosis, survival is less than          Mazzucchelli              Platinum-based chemotherapy                  Lane et al.
                                                 1 year, with frequent extrarenal                    et al.                         for treatment or palliation                        2007 (6)
                                                      extension, regional lymph                     2009 (13) 
                                                      node, brain, bone, adrenal                  Kuroda et al.
                                                     gland and liver metastases                     2014 (24)                                           
                                                    One case occured in kidney                  Mohd et al.                    Surgery in case of tumor                        Xu et al.
                                                           transplant recipient                           2016 (28)                       thrombus, 7 months OS                         2009 (30)
                                             One case with pulmonary, pancreatic       Shimbori et al.               Surgery plus chemotherapy,                  Teegavarapu 
                                                        and cardiac metastases                        2017 (27)                   17.3 months overall survival                et al. 2014 (31)
                                                                                                                                                             Surgery, platinum-based                   Shimbori et al.
                                                                                                                                                       chemotherapy and radiotherapy                   2017 (27)
OS: Overall survival.
in size. The tumor is usually localized to the trigone and the
neck of the bladder, but there are several cases in the
literature in which the prostatic urethra is involved as well
(35). According to other theories, the tumor originates from
metaplastic bladder urothelium or from transformed
neuroendocrine cells, especially in the region of the trigone
(12). The exact cellular origin of bladder NET is still
unknown; however, it has been postulated that NETs may
arise from NE cells of different kind of reactive lesions (36).
Microscopic features are similar to NETs located in other
organs. Histologically, the tumor cells are cuboidal or
columnar with abundant amphophilic cytoplasm, and they
are arranged in an insular, acini, trabecular, or
pseudoglandular pattern in a vascular stroma with ﬁnely
stippled chromatin and inconspicuous nucleoli. Mitotic
ﬁgures are infrequent, and no tumor cell necrosis can be
seen. Typically, the tumor cells are found in the lamina
propria and are positive for NE markers (chromogranin A,
synaptophysin, and CD56) and cytokeratins (23, 34). In
addition, prostate-specific acid phosphatase (PAP) expression
was detected. No other prostate marker positivity can be
detected (36). Due to the lack of long-term follow-up data,
the prognosis cannot be exactly estimated.
Small cell neuroendocrine carcinoma of the urinary bladder.
0.5-1% of all primary bladder malignancies are SCNECs. Its
pure form is rare; half of the cases are mixed with urothelial
carcinoma, adenocarcinoma, squamous cell carcinoma, and/or
sarcomatoid features (37). SCNEC has a slight male
predominance with a male-to-female ratio of 3:1. The mean
age of the patients is 66 years (23). 80% of the patients have a
history of cigarette smoking. Common clinical symptom of this
disease is hematuria. Sometimes local irritation, pain in the
pelvic region, or urinary obstruction may also occur (38). In
most of the cases, macroscopic histological examination
reveals large solid, polypoid, or nodular, ulcerated mass with
muscle or fat tissue invasion. The fundus, the lateral and
posterior walls of the bladder are most commonly involved
(39). Macroscopically, SCNEC is not different from urothelial
carcinoma. SCNEC usually has a polypoid, solid, or ulcerative
appearance with deep invasion of the bladder wall (40).
Microscopically, histological features of bladder SCENC are
similar to those of small cell carcinoma of the lungs. The tumor
is composed of small to intermediate size cells with scanty
cytoplasm, inconspicuous nucleoli, and in several cases, the
typical salt-and-pepper chromatin can be observed as well (41).
Brisk mitotic activity, vascular invasion, and necrosis can also
be detected (23). Mitotic count and Ki67 index are important
for grading (42). Tumor cells express both epithelial and
neuroendocrine markers. Chromogranin A, synaptophysin,
neuron-specific enolase, CD57, CD56, protein gene product
9.5, and ‘dot-like’ cytokeratin positivity are characteristic for
this kind of tomur. Chromogranin A is a specific but quite
insensitive marker, which is expressed in 30% of the tumors.
The Ki67 index is variable, and nuclear accumulation of p53
protein can be observed as well (43-45). The use of TTF-1 to
differentiate the tumor from pulmonary small cell carcinoma
is dubious as 25-39% of bladder small cell carcinomas also
express TTF-1. Several allelic and chromosomal losses,
deletions, and gains have already been identified. Some of
these affected oncogenes, like MYC has a high amplification
level in SCNEC of the bladder (43). Genetic trials proved p53
and RB1 to be the most frequently altered genes in 90% of
patients with small cell carcinoma. Bladder-specific mutations
in the TERT promoter have been reported. These genetic
results are more likely to refer to urothelial carcinoma rather
than small cell lung cancer (46). Bladder SCNEC has an
aggressive clinical course (23, 47). CT images of bladder small
cell cancer show a heterogeneous broad-based polypoid mass
with extensive local invasion (at least T3 or T4 stage) (3).
Bladder SCNEC tends to have a better outcome than the small
cell carcinoma of prostate (48). Most available treatment
options can also be administered in case of small cell
carcinoma of the lungs. Early diagnosis of the disease as well
as surgery, neoadjuvant, adjuvant, or palliative chemotherapy
with or without radiotherapy are the cornerstones of patient
care (13, 48-50). Details about prognosis and therapy are
shown in Table III (13, 23, 35, 41, 42, 44, 47-60).
Large cell neuroendocrine tumor of the urinary bladder.
Large cell neuroendocrine tumor (LCNEC) of the bladder is
an extremely rare form of cancer with fewer than 25 reported
cases (61). The disease mainly develops in elderly male
patients (36). Histologically, LCNEC is identical to large cell
carcinoma of the lungs. Tumor cells are large with a
polygonal shape, low nuclear to cytoplasmic ratio, coarse
nuclear chromatin, prominent nucleoli, and frequent mitotic
ﬁgures (38, 62). Admixture of LCNEC and other forms of
bladder cancer including urothelial carcinoma, squamous cell
carcinoma, adenocarcinoma, and sarcomatoid carcinoma can
also be detected (63). The genetic background is unknown
due to the rarity of the disease (36). Immunohistochemically,
the tumor cells show a strong reaction for cytokeratins
(AE1/AE3, CAM5.2) and EMA. The expression of NE
markers mainly confirm the diagnosis; however,
chromogranin A is expressed more frequently in bladder
SCNEC than in LCNEC (62). The prognosis of pure bladder
large cell carcinoma is similar to small cell cancer (13). The
therapeutic options are presented in Table III (13, 61, 63-65).
Neuroendocrine tumors of the prostate
Neuroendocrine differentiation in prostate cancer. Almost all
prostate carcinomas (PCA) have focal NE differentiation, but
confluent zones with focal NE cells or NE cell clusters (<50
cells) can be detected only in 5-10% of cases. The role and
origin of prostatic NE cells are unknown (66). There are some
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Table III. Neuroendocrine tumors of the urinary bladder: prognostic and therapeutic data from current references.
                                                                   Prognosis                                  References                            Potential therapy                              References
Urinary bladder
  Well-diff. NET                     Lymphatic metastasis in 25% of             Mazzucchelli                                Excision                                    Chen et al.
                                                  cases, mixed tpyes NETs with                     et al.                                                                                           2011 (35)
                                                  adenocarcinoma are aggressive                 2009 (13)
  SCNEC                                  Aggressive behavior, 1.7 years               Cheng et al.              Surgery with adjuvant cisplatin-                 Ghadouane 
                                                         median survival time,                        2004, (23)                         based chemotherapy                                et al.
                                                    anecdotal long-time survival                Choong et al.                                                                                   2003 (52)
                                                                                                                       2005(47)
                                                 12.7 months median OS, better               Asmis et al.          After cystectomy the median cancer-           Siefker et al.
                                                 outcome than prostatic SCNEC                 2006 (48)                specific survival was 23 months,                 2004 (53)
                                                                                                                                              combined with preoperative chemotherapy 
                                                                                                                                                          the 5-year survival was 78%
                                         In 40% of cases brain metastasis occured      Moretto et al.          Neoadjuvant chemotherapy before             Siefker et al.
                                                                                                                      2013 (44)         surgery has favourable effect on survival          2004 (53), 
                                                                                                                                                                                                                            Prelaj et al.
                                                                                                                                                                                                                              2016 (51)
                                             In 28-80% of cases lymphatic, liver,          Zheng et al.      Etoposide, cisplatin, carboplatin for pure       Manunta et al.
                                               lung and bone metasteses occured               2015 (41)                forms; methotrexate, vincristine,                 2005 (54)
                                                                                                                                                       adriamycin, cyclophosphamide, 
                                                                                                                                                  etoposide or cisplatin for mixed types
                                            At the time of diagnosis 95% of cases         Zheng et al.          Treated with transurethral resection,             Tunc et al.
                                              are present in advanced local stage             2015 (41),             adjuvant carboplatin-based chemo-               2006 (55)
                                                              (pT2 or higher)                             Prelaj et al.                 and radiotherapy, 30 months                  Mazzucchelli 
                                                                                                                      2016 (51)                          disease-free survival                       et al. 2009 (13)
                                                                                                                                                    Early cisplatin-based chemotherapy
                                                                                                                                             Neoadjuvant platinum-based chemotherapy   Ruoppolo et al.
                                                                                                                                                       followed by aggressive surgery                   2010 (56)
                                                                                                                                                Platinum based chemotherapy followed        Macedo et al.
                                                                                                                                                                  by local treatment                             2011 (57), 
                                                                                                                                                                                                                            Thota et al.
                                                                                                                                                                                                                              2013 (50)
                                                                                                                                                            Cystectomy plus adjuvant                      Guo et al.
                                                                                                                                                       chemotherapy and radiotherapy                   2012 (49)
                                                                                                                                             Case with lymphatic, hepatic, adrenal, lung     Cerulli et al.
                                                                                                                                                 metastases with two different cycles of            2012 (58)
                                                                                                                                                  cisplatin chemotherapy, no resoponse
                                                                                                                                                  Surgery with neoadjuvant or adjuvant         Moretto et al.
                                                                                                                                                  chemotherapy and radiochemotherapy            2013 (44)
                                                                                                                                              (doses from 35 Gy/20, 64 Gy/32 to 70 Gy)                 
                                                                                                                                                          Palliative chemotherapy for                   Thota et al.
                                                                                                                                                                  metastatic disease                              2013 (50)
                                                                                                                                                        Cisplatin-based chemotherapy               Aragón-Tovar 
                                                                                                                                                              plus radical cystectomy                    et al. 2014 (59)
                                                                                                                                                            Surgery/cystectomy alone                     Erdem et al.
                                                                                                                                                                       is inadequat                                   2016 (60)
                                                                                                                                                     Transurethral bladder resection is            Ghervan et al.
                                                                                                                                                               inadequate for therapy                          2017 (42)
  LCNEC                             Similar to SCNEC of urinary bladder         Mazzucchelli        Aggressive surgery with neoadjuvant           Evans et al.
                                                                                                                          et al.                or adjuvant etoposide and platinum-              2002 (65),
                                                                                                                      2009 (13)                   based chemotherapy, surgery                 Coelho et al.
                                                                                                                                                           alone is not recommended                       2014(61)
                                          Increased risk for developing of prostate      Zakaria et al.          7 months survival after 5 cycles of           Colarossi et al.
                                                     cancer after external beam                     2017 (64)               chemotherapy with etoposide and                2013 (63)
                                                    radiation and brachytherapy                                                       cisplatin followed by surgery
ANTICANCER RESEARCH 38: 3243-3254 (2018)
3248
Table IV. Neuroendocrine tumors of the prostate: prognostic and therapeutic data from current references.
                                                                   Prognosis                                  References                            Potential therapy                              References
Prostate carcinoma
  Adenocc with NED             Metastatic androgen-independent           Cheville et al.                      Aurora A inhibitor in                        clinical trial 
                                                  prostate cancer with focal NE                  2002 (75)                    metastatic castrate-resistant                          (77)
                                               differentiation has poor prognosis                                                   and neuroendocrine prostate
                                         Serum chromogranin A does not correlate     Berruti et al.             Lanreotide with dexamathasone                Koutsilieris 
                                                 with response to chemotherapy                 2005 (95)                           with 7 months PFS                        et al. 2001 (96)
                                                No correlation of neuroendocrine                Fine SW                Lanreotide with ethinylestradiol                Di Silverio 
                                             differentiation with clinical outcome              2007 (5)                                with 18.5 PFS                            et al. 2003 (97)
                                                    Ki-67 index as independent                Komiya et al.              Serotonin receptor antagonists                 Dizeyi et al.
                                                             prognostic factor                             2009 (66)                                                                                       2005 (79)
                                           AURKA and/or n-MYC ampliﬁcations   Beltran 2011 (76),         Bombesin-like/gastrin-releasing              Stangelberger 
                                                    might be a predictive factor              Terry and Beltran         peptide antagonists in androgen-                 et al. 2006 
                                                                                                                      2014 (67)                    independent prostate cancer                          (78)
                                                                                                                                                            Three courses of cisplatin                     Inoue et al.
                                                                                                                                                                     and irinotecan                                 2007 (98)
                                                                                                                                                               mTOR pathway in the                       Garcia et al.
                                                                                                                                                                       management                                  2008 (99)
                                                                                                                                                                Somatostatin analogs                        Komiya et al.
                                                                                                                                                                                                                              2009 (66)
                                                                                                                                                High doses of paclitaxel and carboplatin         Maebayashi 
                                                                                                                                                           then irradiation (60+10Gy)                 et al. 2015 (100)
                                                                                                                                                            Etoposide and carboplatin                      Wei et al.
                                                                                                                                                                 then docetaxel only                           2016 (101)
                                                                                                                                                    Intracellular chemokine CXCL12γ               Jung et al.
                                                                                                                                                                 as therapeutic target                           2018 (102)
  Well-diff. NET                    Relatively indolent and favorable             Mazzucchelli                 Neoadjuvant chemotherapy                     Tash et al.
                                                                                                                 et al. 2009 (13)              and radical prostatectomy for                    2002 (82)
                                                                                                                                                    metastatic well-differentiated NETs
  SCNEC                                Testicle metastasis 2.5 years after               Schneider              Cisplatin-based chemotherapy plus           Benchenkroun 
                                                   androgen deprivation therapy             et al. 2006 (103)         radiotherapy failed to improve the                   et al.
                                                                                                                                                   survival, patient died after 4 months             2002 (104), 
                                                                                                                                                                                                                             Stein et al.
                                                                                                                                                                                                                             2008 (105)
                                         No difference in prognosis between pure      Mazzucchelli         Octreotide therapy recived remission            Spieth et al.
                                        small cell and mixed with adenocarcinoma   et al. 2009 (13)                                                                                  2002 (106)
                                             Small cell component usually means         Mazzucchelli               Combination of doxorubicin,                  Papandreou 
                                                              a terminal phase                         et al. 2009 (13)            etoposide and cisplatin resulted                 et al. 2002 
                                                                                                                                                   5.8 months PFS and 10.5 months OS                  (107)
                                         Aggressive behavior, poor prognosis with     Deorah et al.              Metronomic cyclophosphamide                Berry et al.
                                               19 months median cancer-specific              2012 (93)          and mitoxantrone have favorable effect           2002 (108), 
                                              survival, 2-year and 5-year survival                                                                                                                    Lord et al.
                                                 were 14.3%, 27.5% respectively                                                                                                                       2007 (109)
                                                                                                                                                   Cisplatin plus etoposide, progression            Yashi et al.
                                                                                                                                                             controlling for 7 months                       2006 (110)
                                                                                                                                                Four cycles of irinotecan plus cisplatin,        Komiya et al.
                                                                                                                                              after second cycle neuron-specific enolase         2009 (66)
                                                                                                                                                     level was normalized and after the 
                                                                                                                                                   fourth cycle was complete remission
                                                                                                                                                  Three course intra-arterial infusion of         Uemura et al.
                                                                                                                                                  cisplatin plus ifosfamid, then external            2013 (111)
                                                                                                                                                                      beam radiaton
                                                                                                                                                 Carboplatin plus docetaxel followed by       Aparicio et al.
                                                                                                                                             cisplatin plus etoposide, objective response        2013 (112)
                                                                                                                                                  rate 33%, median survival 16 months
Table IV. Continued
potential theories about the origin of NE cells: (1) NE and
conventional adenocarcinoma components may arise from one
tumor clone with stem cell-like abilities (i.e., epithelial and
NE differentiation) (67); (2) NE tumor cells may evolve from
adenocarcinoma cells by genetic alterations, due to treatment
interventions (i.e., androgen deprivation therapy, radiation and
chemotherapy) or changes in the microenvironment of the
tumor cells (i.e., hypoxia, cytokines, or hormones); (3)
malignant NE phenotype arises from normal prostatic NE cells
(67). Reduced activity and/or expression of the androgen
receptor (AR) can be observed in NE cells, resulting in a
hormone-insensitive cellular population embedded in the
tumor, which may lead to the progression of the disease (67-
69). NE cells are indistinguishable from tumor cell in PCA;
therefore, the identification is based on the expression of NE
markers: chromogranin A, serotonin, and somatostatin.
Prostate-specific markers (prostate specific antigen - PSA,
prostatic acid phosphatase - PAP) positivity can also be found
in case of NE cells (5). There is a relationship between the
elevated proportion of NE differentiation in castrate-resistant
prostate cancer and high serum level of chromogranin A. It
could be an indicator in patients without elevated serum PSA
level (70, 71). Some data show that more than 50% of all
neuroendocrine prostatic carcinoma cases are associated with
prostatic adenocarcinomas and clinically with androgen-
receptor independence. Therefore, in 2013, the Prostate
Cancer Foundation Working Committee on neuroendocrine
PCA suggested the terminology of “AR-negative prostate
cancer” for neuroendocrine prostatic carcinoma. However,
mixed tumors contain AR-positive and also AR-negative cells,
and in rare cases, hybrid tumors can be identified where
neuroendocrine markers and AR are expressed in the same
tumor cells (72). Studies have proven that prolonged androgen
deprivation in androgen sensitive metastatic and also in
primary PCA results in increased neuroendocrine
differentiation (73). Focal NE differentiation develops in 10%
to 100% of prostate adenocarcinomas treated by anrogene
deprivation therapy (ADT), especially in advanced stage but
with relatively low serum PSA (74). The prognosis is
controversial (5), but in fact, prostate cancer with focal NE
differentiation has poor prognosis (13, 75). In order to better
understand the importance of NE differentiation, the molecular
mechanisms also have to be studied. Recently, two proto-
oncogenes have become the center of attention, namely,
cytoplasmic serine/threonine-protein kinase AURKA (Aurora
kinase A) and nuclear transcription factor n-MYC, which
might be responsible for the malignant NE phenotype in
prostate cancers (76). Terry and Beltran have found in their
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Table IV. Continued
                                                                   Prognosis                                  References                            Potential therapy                              References
                                                                                                                                                 Combination of carboplatin, etoposide,        Aparicio et al.
                                                                                                                                                   cyclophosphamide, doxorubicin and             2014 (113)
                                                                                                                                                 vincristine between 4 and 8 cycles and 
                                                                                                                                                           then locoregional methods
                                                                                                                                            Systemic chemotherapy alone or combintion     Parimi et al.
                                                                                                                                                     with androgen deprivation therapy                2014 (73)
                                                                                                                                                         For advanced stage disease is              Campedel et al.
                                                                                                                                                        platinum-based chemotherapy                    2017 (94)
                                                                                                                                              Case report with paraneoplastic syndrome          Peverelli 
                                                                                                                                          of inappropriate antidiuretic hormone secretion         et al.
                                                                                                                                                  and high sensitivity for chemotherapy            2017 (114)
                                                                                                                                                     Platinum-based chemotherapy, but           Akamatsu et al.
                                                                                                                                                           response duration is short                      2018 (115)
  LCNEC                                   Rapid course, poor prognosis                 Evans et al.                Platinum based chemotherapy                 Evans et al.
                                                                                                                      2006 (95)                        with 7 months survival                          2006 (95)
                                                                                                                                                     Neoadjuvant chemotherapy (taxol,             Okoye et al.
                                                                                                                                                           vepesid and cisplatin) with                     2013 (116)
                                                                                                                                                          Lupron followed by radical 
                                                                                                                                                            prostatectomy and pelvic
                                                                                                                                                             lymphadenectomy with 
                                                                                                                                                                 13 months survival                                     
                                                                                                                                                      Effects of icaritin in mice model                  Sun et al.
                                                                                                                                                                                                                             2016 (117)
OS: Overall survival; PFS: progression-free survival.   
study that the inhibition of AURKA blocks the growth of NE
cells in vitro and in vivo. Detection of AURKA may lead to
further therapeutic options (77). Prostatic neuroendocrine
tumors are treated with combined somatostatin analogs that
have a high therapeutic index (66). Bombesin/GRP antagonists
and serotonin antagonists may be regarded as further
therapeutic options (78, 79). Castration-resistant prostate
cancer is usually fatal, and successful management is still a
problem. Nelson et al. have proposed a theory about four
different stages of so-called adaptation in prostate cancer on
the basis of androgenic ligands and the activity of AR (80).
Well-differentiated neuroendocrine tumor of the prostate. Well-
differentiated neuroendocrine tumors of the prostate are
extremely rare; only a few cases of them have been reported
(81, 82). No specific age group in which prostatic NET
develops more frequently can be identified; nevertheless, some
authors suggest that it is usually found accidentally in elderly
patients, while others report that locally advanced and
metastatic diseases are more frequent in younger adults (13,
73). Clinical symptoms are hematuria, burning nocturia,
frequent urination, and different symptoms of urinary retention.
Macroscopically, the size of the tumor is variable, and
sometimes infiltrates the entire prostate. For the diagnosis of
pure NET, conventional PCA with NE differentiation need to
be excluded, which could be challenging (5). Histological
features are similar to NETs of other organs: trabecular, insular,
mixed architectural patterns of generally polygonal or spindle-
shaped cells, with low-grade cytological features and “salt and
pepper” chromatin. The cytoplasm is abundant and
eosinophilic, and mitotic figures are uncommon (81, 83). The
cells are positive for chromogranin A and synaptophysin, and
negative for PSA and PAP. If a tumor represents nested
architecture and uniform nuclei with positive staining for PSA
and NE markers, a “NET-like” PCA should be considered (73,
74). The prognosis is hard to define because of their rarity, but
nowadays, it is considered to be favorable (13).
Small cell neuroendocrine carcinoma of the prostate. Prostatic
SCNEC represents approximately 1-5% of all prostate
malignancies (5). Local symptoms are similar to those
represented in case of conventional PCA, but in a few cases,
paraneoplastic syndrome develops, such as Cushing syndrome,
hypercalcemia, syndrome of inappropriate antidiuretic
hormone secretion, and Eaton–Lambert syndrome (84-86).
The serum PSA concentration is variable (87). Prostatic
SCNEC may develop in a pure form or can be mixed with
acinar PCA (13, 73). At least 25% of patients with advanced
PCA may eventually develop SCNEC. The number of NE
differentiation in PCA may increase because of the novel AR
targeted therapies for castration-resistance PCA (88).
Microscopically, SCNEC has similar histological features to
small cell carcinoma in other organs with minimal cytoplasm,
indistinct cell borders, nuclear molding, extensive tumor cell
necrosis, high mitotic rate, and nuclear fragility (73).
Approximately 50% of the cases express TTF1, hence the use
of TTF-1 expression cannot distinguish between primary
prostatic SCNEC and metastatic small cell carcinoma of other
organs (73). Chromogranin and synaptophysin staining is
intense in 90% and 17% of cases, respectively (5). 24% of
cases are diffusely positive for PSA and PAP, which suggests
that there is a link between acinar PCA and prostatic SCNEC
(89-91). In the diagnostic process, fluorescence in situ
hybridization (FISH) or reverse transcription polymerase chain
reaction may be useful in order to detect a gene fusion
between the ETS family member gene ERG and TMPRSS2
gene. Half of the prostatic small cell cases are positive for
TMPRSS2-ERG gene fusion by FISH (92). Grading of small
cell cancer should not be done according to the Gleason
system, although some pathologists still give Gleason score
with an additional comment (13). Prostatic SCNEC has one
of the most aggressive behaviors of all prostate cancers, often
in advanced local stage (93). Small cell carcinomas of the
prostate are thought to be identical to small cell carcinomas
of the lungs. Therefore, cytotoxic agents given in case of small
cell carcinoma of the lungs can be usually administered to
patients with small cell carcinoma of the prostate as well (94),
but there are also other therapeutic options available.
Large cell neuroendocrine carcinoma of the prostate. Few cases
of LCNEC have been reported (5, 95). Histologically, it shows
similar features to the ones seen in other organs. Typically, the
tumor cells have abundant amphophilic cytoplasm and large
nuclei with coarse chromatin and prominent nucleoli. Brisk
mitotic activity and geographic necrosis can be noticed as well.
The tumor cells are larger than the cells of small cell carcinoma
or conventional prostatic adenocarcinoma (73). However, it is
difficult to distinguish LCNEC from Gleason 5 + 5 PCA, hence
the chance of a misdiagnosis is quite high (95). Immunohisto-
chemically, these tumors are strongly positive for chromogranin
A, synaptophysin, CD56, CD57, and P504S/α-methylacyl CoA
racemase. A focally positive staining pattern can be identified
for PSA and PAP in LCNEC, and they are negative for
androgen receptor. Their prognosis is poor, and they are
frequently present with distant metastases at the time of their
discovery. They might be treated with long-term hormone
therapy (95). Table IV contains further prognostic and
therapeutic details for all prostatic neuroendocrine tumors (5,
13, 66, 67, 73, 75-79, 82, 93-117).
Discussion
As a result of the rarity of these tumors, there is a diagnostic
challenge and therapeutic dilemma. To distinguish between a
NET and an undifferentiated tumor of the GU tract can become
an exceedingly problematic task, and that is why special
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immunohistochemichal stainings, beyond the standard markers,
should be ordered in such cases. NE markers have good
specificity although their sensitivity is different. Since
neuroendicrine tumors are more common in the lungs and the
gut than in the GU tract, the possibility of a metastatic
involvement from these sites should be considered first.
Because the pathologist has limited options, the exclusion of a
metastasis in other organs is mainly based on the clinical
parameters. The outcome of these tumors is poor; therefore, an
exact histological and immunohistochemical verification is
needed to prevent misdiagnosis. No guidelines are available
regarding the optimum management; thus, different treatment
strategies are applied to improve the poor prognosis of the
disease. The therapy of renal and bladder NET is based on the
management of NET in other sites. There are some important
approaches for the management of prostatic NET. Prostatic
NETs are mainly AR negative. Data show that advanced
prostatic cancer often presents with mixed histological features,
with AR-dependent and AR-independent tumor cells; moreover,
hybrid tumors can also be detected with both NE markers and
AR expressing tumor cells. Neuroendocrine differentiation in
prostatic adenocarcinoma characteristically occurs in AR-
independent/castrate-resistant prostate cancers. The therapeutic
options involve chemotherapy, somatostatin analogs, and
bombesin-like antagonists. Somatostatin analogs are the basic
therapeutic regimens in case of well-differentiated NETs.
References
1 Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH,
Wiseman GA and Kvols LK: The NANETS Consensus
Guidelines for the Diagnosis and Management of Poorly
Differentiated (High-Grade) Extrapulmonary Neuroendocrine
Carcinomas. Pancreas 39(6): 799-800, 2010.
2 Lane BR, Jour G and Zhou M: Renal neuroendocrine tumors.
Indian J Urol 25(2): 155-160, 2009.
3 Katabathina VS, Vikram R, Olaoya A, Paspulati RM, Nicolas
MM, Rao P, Zaheer A and Prasad SR: Neuroendocrine
neoplasms of the genitourinary tract in adults: cross-sectional
imaging spectrum. Abdom Radiol 42: 1472-1484, 2017.
4 Moch H, Humphrey PA, Ulbright TM and Reuter VE: WHO
Classification of Tumours of the Urinary System and Male
Genital Organs. Fourth edition. IARC WHO Classification of
Tumours, No 8, 2016.
5 Fine SW: Neuroendocrine lesions of the genitourinary tract.
Adv Anat Pathol 14(4): 286-296, 2007.
6 Lane BR, Chery F, Jour G, Sercia L, Magi-Galluzzi C, Novick
AC and Zhou M: Renal neuroendocrine tumours: a
clinicopathological study. BJU Int 100(5): 1030-1035, 2007.
7 Mardi K, Negi L and Srivastava S: Well differentiated neuro-
endocrine tumor of the kidney: Report of a rare case with review
of literature. Indian J Pathol Microbiol 60(1): 105-107, 2017.
8 Omiyale AO and Venyo AK: Primary carcinoid tumour of the
kidney: a review of the literature. Adv Urol 2013: 579396, 2013.
9 Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds.).: World
Health Organization classification of tumours: pathology and
genetics of tumours of the urinary system and male genital
organs. Lyon, IARC, 2004.
10 Romero FR, Rais-Bahrami S, Permpongkosol S, Fine SW,
Kohanim S and Jarrett TW: Primary carcinoid tumors of the
kidney. J Urol 176: 2359-2366, 2006.
11 Hansel DE, Epstein JI, Berbescu E, Fine SW, Young RH and
Cheville JC: Renal carcinoid tumor: a clinicopathologic study
of 21 cases. Am J Surg Pathol 31(10): 1539-1544, 2007.
12 Murali R, Kneale K, Lalak N and Delprado W: Carcinoid
Tumors of the Urinary Tract and Prostate. Arch Pathol Lab Med
130: 1693-1706, 2006.
13 Mazzucchelli R, Morichetti D, Lopez-Beltran A, Cheng L,
Scarpelli M, Kirkali Z and Montironi R: Neuroendocrine
tumours of the urinary system and male genital organs: clinical
signiﬁcance. BJU INTERNATIONAL 103: 1464-1470, 2009.
14 Quinchon JF, Aubert S, Biserte J, Lemaitre L, Gosselin B and
Leroy X: Primary atypical carcinoid of the kidney: a
classification is needed. Pathology 35(4): 353-355, 2003.
15 Kubota Y, Seike K, Maeda S and Tashiro K: Case of primary
renal carcinoid tumor with hemorrhage. Hinyokika Kiyo 56(4):
225-228, 2010.
16 Motta L, Candiano G and Pepe P: Neuroendocrine tumor in a
horseshoe kidney. Case report and updated follow-up of cases
reported in the literature. Urol Int 73(4): 361-364, 2004.
17 Gedaly R, Jeon H, Johnston TD, McHugh PP, Rowland RG and
Ranjan D: Surgical treatment of a rare primary renal carcinoid
tumor with liver metastasis. World J Surg Oncol 6: 41, 2008.
18 Finley DS, Narula N, Valera VA, Merino MJ, Fruehauf J, Wu
ML, Linehan WM and Clayman RV: Immunohistochemical
basis for adjuvant anti-angiogenic targeted therapy for renal
carcinoid: initial case report. Urol Oncol 29(1): 85-89, 2011.
19 Inagaki Y, Fujita K, Nakai Y, Takayama H, Tsujimura A and
Nonomura N: Renal neuroendocrine tumor (carcinoid) : a case
report. Hinyokika Kiyo 59(11): 723-727, 2013.
20 Gonzalez-Lois C, Madero S, Redondo P, Alonso I, Salas A and
Angeles Montalbán M: Small cell carcinoma of the kidney: a
case report and review of the literature. Arch Pathol Lab Med
125: 796-798, 2001.
21 Akkaya BK, Mustafa U, Esin O, Turker K and Gulten K:
Primary small cell carcinoma of the kidney. Urol Oncol 21: 11-
13, 2003.
22 Si Q, Dancer J, Stanton ML, Tamboli P, Ro JY, Czerniak BA,
Shen SS and Guo CC: Small cell carcinoma of the kidney: a
clinicopathologic study of 14 cases. Hum Pathol 42: 1792-1798,
2011.
23 Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT,
Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch
MO and Eble JN : Small cell carcinoma of the urinary bladder:
a clinicopathologic analysis of 64 patients. Cancer 101: 957-
962, 2004.
24 Kuroda N, Imamura Y and Hamashima T: Review of small cell
carcinoma of the kidney with focus on clinical and
pathobiological aspects. Pol J Pathol 65(1): 15-19, 2014.
25 Palumbo C, Talso M, Dell'Orto PG, Cozzi G, De Lorenzis E,
Conti A, Maggioni M, Cesare Rocco BM, Maggioni A and
Rocco F: Primary large cell neuroendocrine carcinoma of the
renal pelvis: a case report. Urologia 81: 57-59, 2014.
26 Wann C, John NT and Kumar RM: Primary renal large cell
neuroendocrine carcinoma in a young man. J Clin Diagn Res
8: ND08-9, 2014. 
Pósfai et al: Neuroendocrine Neoplasms of the Genitourinary Tract (Review)
3251
27 Shimbori M, Osaka K and Kawahara T: Large cell
neuroendocrine carcinoma of the kidney with cardiac
metastasis: a case report. J Med Case Rep 11(1): 297, 2017.
28 Mohd KA, Draman CR, Seman MR, Kalavathy R and Mubarak
MY: Metastatic neuroendocrine tumor of small cell type in a
kidney transplant recipient. Saudi J Kidney Dis Transpl 27(4):
787-790, 2016. 
29 Piedra Lara JD, Tejido Sánchez A, García de la Torre JP,
Capitán Manjón C, Cruceyra Betriu G and Leiva Galvis O:
Neuroendocrine renal carcinoma. Presentation of a case. Arch
Esp Urol 56(2): 178-181, 2003. 
30 Xu G, Chen J and Zhang Z: Primary small cell carcinoma of
the kidney with tumour thrombus extension into the inferior
vena cava and pulmonary artery: a case report and review of
the literature. J Int Med Res 37(2): 587-593, 2009.
31 Teegavarapu PS, Rao P, Matrana M, Cauley DH, Wood CG and
Tannir NM: Neuroendocrine tumors of the kidney: a single
institution experience. Clin Genitourin Cancer 12(6): 422-427,
2014.
32 Martignoni G and Eble JN: Carcinoid tumors of the urinary
bladder: immunohistochemical study of 2 cases and review of
the literature. Arch Pathol Lab Med 127: e22-24, 2003.
33 Baydar DE and Tasar C: Carcinoid tumor in the urinary bladder:
unreported features. Am J Surg Pathol 35: 1754-1757, 2011. 
34 Sugihara A, Kajio K, Yoshimoto T, Tsujimura T, Iwasaki T,
Yamada N, Terada N, Tsuji M, Nojima M, Yabumoto H, Mori
Y and Shima H: Primary carcinoid tumor of the urinary bladder.
Int Urol Nephrol 33(1): 53-57, 2002. 
35 Chen YB and Epstein JI: Primary carcinoid tumors of the
urinary bladder and prostatic urethra: a clinicopathologic study
of 6 cases. Am J Surg Pathol 35: 442-446, 2011.
36 Kouba E and Cheng L: Neuroendocrine tumors of the urinary
bladder according to the 2016 World Health Organization
Classification: Molecular and clinical characteristics. Endocr
Pathol 27(3): 188-199, 2016.
37 Trias I, Algaba F, Condom E, Español I, Seguí J, Orsola I,
Villavicencio H and García Del Muro X: Small cell carcinoma
of the urinary bladder. Presentation of 23 cases and review of
134 published cases. Eur Urol 39(1): 85-90, 2001.
38 Bertaccini A, Marchiori D, Cricca A, Garofalo M, Giovannini
C, Manferrari F, Gerace TG, Pernetti R and Martorana G:
Neuroendocrine carcinoma of the urinary bladder: case report
and review of the literature. Anticancer Res 28(2B): 1369-1372,
2008.
39 Mukesh M, Cook N, Hollingdale AE, Ainsworth NL and
Russell SG: Small cell carcinoma of the urinary bladder: a 15-
year retrospective review of treatment and survival in the
Anglian Cancer Network. BJU Int 103(6): 747-752, 2009.
40 Wang X, MacLennan GT, Lopez Beltran A and Cheng L: Small
cell carcinoma of the urinary bladder: histogenesis, genetics,
diagnosis, biomarkers, treatment, and prognosis. Appl
Immunohistochem Mol Morphol 15: 8-18, 2007.
41 Zheng X, Liu D, Fallon JT and Zhong M: Distinct genetic
alterations in small cell carcinoma from different anatomic
sites. Exp Hematol Oncol 4: 2, 2015.
42 Ghervan L, Zaharie A, Ene B and Elec FI: Small-cell carcinoma
of the urinary bladder: where do we stand? Clujul Med 90(1):
13-17, 2017.
43 Church DN and Bahl A: Small cell carcinoma of the bladder.
Cancer Treat Rev 32(8): 588-593, 2006.
44 Moretto P, Wood L, Emmenegger U, Blais N, Mukherjee SD,
Winquist E, Belanger EC, Macrae R, Balogh A, Cagiannos I,
Kassouf W, Black P, Czaykowski P, Gingerich J, North S, Ernst
S, Richter S, Sridhar S, Reaume MN, Soulieres D, Eisen A and
Canil CM: Management of small cell carcinoma of the bladder:
Consensus guidelines from the Canadian Association of
Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc
J 7(1-2): E44-56, 2013.
45 Zhou H, Liu L, Yu G, Qu GM, Gong PY, Yu X and Yang P:
Analysis of clinicopathological features and prognostic factors
in 39 cases of bladder neuroendocrine carcinoma. Anticancer
Res 37(8): 4529-4537, 2017. 
46 Chang MT, Penson AV, Desai NB, Socci ND, Shen R, Seshan
VE, Kundra R, Abeshouse A, Viale A, Cha EK, Hao X, Reuter
VE, Rudin CM, Bochner BH, Rosenberg JE, Bajorin DF,
Schultz N, Berger MF, Iyer G, Solit DB, Al-Ahmadie HA and
Taylor BS: Small cell carcinomas of the bladder and lung are
characterized by a convergent but distinct pathogenesis. Clin
Cancer Res 24(8): 1965-1973, 2018.
47 Choong NW, Quevedo JF and Kaur JS: Small cell carcinoma
of the urinary bladder. The Mayo Clinic experience. Cancer
103(6): 1172-1178, 2005.
48 Asmis TR, Reaume MN, Dahrouge S and Malone S:
Genitourinary small cell carcinoma: a retrospective review of
treatment and survival patterns at The Ottawa Hospital
Regional Cancer Center. BJU Int 97(4): 711-715, 2006.
49 Guo AT, Chen W and Wei LX: Clinical and pathologic
characteristics of small cell neuroendocrine carcinoma of urinary
tract. Zhonghua Bing Li Xue Za Zhi 41(11): 747-751, 2012.
50 Thota S, Kistangari G, Daw H and Spiro T: A clinical review
of small-cell carcinoma of the urinary bladder. Clin Genitourin
Cancer 11(2): 73-77, 2013.
51 Prelaj A, Rebuzzi SE, Magliocca FM, Speranza I, Corongiu E,
Borgoni G, Perugia G, Liberti M and Bianco V: Neoadjuvant
chemotherapy in neuroendocrine bladder cancer: a case report.
Am J Case Reports 17: 248-253, 2016.
52 Ghadouane M, Zannoud M, Alami M, Albouzidi A, Labraimi A,
Safi L and Abbar M: Small cell neuroendocrine carcinoma of the
bladder. A new case report Ann Urol (Paris) 37(2): 75-78, 2003.
53 Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C,
Shen Y, Pisters LL, Grossman HB, Swanson DA and Millikan
RE: Evidence supporting preoperative chemotherapy for small
cell carcinoma of the bladder: a retrospective review of the
M. D. Anderson cancer experience. J Urol 172(2): 481-484,
2004. 
54 Manunta A, Vincendeau S, Kiriakou G, Lobel B and Guillé F:
Non-transitional cell bladder carcinomas. BJU Int 95: 497-502,
2005.
55 Tunc B, Ozguroglu M, Demirkesen O, Alan C, Durak H,
Dincbas FO and Kural AR: Small cell carcinoma of the bladder:
a case report and review of the literature. Int Urol Nephrol
38(1): 15-19, 2006.
56 Ruoppolo M, Pezzica E, Milesi R, Corti D, Mercurio P and
Fragapane G : Neuroendocrine small-cell bladder cancer: our
experience. Urologia 77(17): 64-71, 2010.
57 Macedo LT, Ribeiro J, Curigliano G, Fumagalli L, Locatelli M,
Carvalheira JB, Quintela A, Bertelli S and De Cobelli O:
Multidisciplinary approach in the treatment of patients with
small cell bladder carcinoma. Eur J Surg Oncol 37(7): 558-
562, 2011.
ANTICANCER RESEARCH 38: 3243-3254 (2018)
3252
58 Cerulli C, Busetto GM, Antonini G, Giovannone R, Di Placido
M, Soda G, De Berardinis E and Gentile V: Primary metastatic
neuroendocrine small cell bladder cancer: a case report and
literature review. Urol Int 88(3): 365-369, 2012.
59 Aragón-Tovar AR, Pineda-Rodríguez ME, Puente-Gallegos FE
and Zavala-Pompa A: Neuroendocrine carcinoma of the urinary
bladder. A case report. Cir Cir 82(3): 338-343, 2014.
60 Erdem GU, Özdemir NY, Demirci NS, Şahin S, Bozkaya Y and
Zengin N: Small cell carcinoma of the urinary bladder:
changing trends in the current literature. Curr Med Res Opin
32(6): 1013-1021, 2016.
61 Coelho HMP, Pereira BAGJ and Caetano PAST: Large cell
neuroendocrine carcinoma of the urinary bladder: case report
and review. Curr Urol 7: 155-159, 2014.
62 Gupta S, Thompson RH, Boorjian SA, Thapa P, Hernandez LP,
Jimenez RE, Costello BA, Frank I and Cheville JC: High grade
neuroendocrine carcinoma of the urinary bladder treated by
radical cystectomy: a series of small cell, mixed neuroendocrine
and large cell neuroendocrine carcinoma. Pathology 47(6): 533-
542, 2015.
63 Colarossi C, Pino P and Giuffrida D: Large cell neuroendocrine
carcinoma (LCNEC) of the urinary bladder: a case report.
Diagn Pathol 8: 19, 2013.
64 Zakaria A, Al Share B, Kollepara S and Vakhariya C: External
beam radiation and brachytherapy for prostate cancer: Is it a
possible trigger of large cell neuroendocrine carcinoma of the
urinary bladder? Case Rep Oncol Med 2017: 1853985, 2017.
65 Evans AJ, Al-Maghrabi J, Tsihlias J, Lajoie G, Sweet JM and
Chapman WB: Primary large cell neuroendocrine carcinoma of the
urinary bladder. Arch Pathol Lab Med 126(10): 1229-1232, 2002.
66 Komiya A, Suzuki H and Imamoto T: Neuroendocrine
differentiation in the progression of prostate cancer. Int J Urol
16: 37-44, 2009.
67 Terry S and Beltran H: The many faces of neuroendocrine
differentiation in prostate cancer progression. Front Oncol 4:
60, 2014.
68 Wright ME, Tsai MJ and Aebersold R: Androgen receptor
represses the neuroendocrine transdifferentiation process in
prostate cancer cells. Mol Endocrinol 17: 1726-1737, 2003.
69 Abstracts of the 27th annual meeting of the Italian Society of Uro-
Oncology (SIUrO). Anticancer Res 37(4): 2051-2158, 2017. 
70 Hirano D, Okada Y, Minei S, Takimoto Y and Nemoto N:
Neuroendocrinedifferentiation in hormone refractory prostate
cancer following androgen deprivation therapy. Eur Urol 45:
586-592, 2004.
71 Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K
and Ichikawa T: Changes in chromogranin a serum levels
during endocrine therapy in metastatic prostate cancer patients.
Eur Urol 48: 224-229, 2005.
72 Beltran H, Tomlins S and Aparicio A: Aggressive variants of
castration-resistant prostate cancer. Clin Cancer Res 20(11):
2846-2850, 2014.
73 Parimi V, Goyal R, Poropatich K and Yang XJ: Neuroendocrine
differentiation of prostate cancer: a review. Am J Clin Exp Urol
2(4): 273-285, 2014.
74 Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM,
Reuter VE, Robinson BD, Troncoso P and Rubin MA: Proposed
morphologic classification of prostate cancer with
neuroendocrine differentiation. Am J Surg Pathol 38: 756-767,
2014.
75 Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz
VS, Sebo TJ, Davis B and Blute ML: Metastatic prostate
carcinoma to bone: clinical and pathologic features associated
with cancer-specific survival. Cancer 95(5): 1028-1036, 2002.
76 Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald
TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson
JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ,
Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis
F, Nanus DM and Rubin MA: Molecular characterization of
neuroendocrine prostate cancer and identification of new drug
targets. Cancer Discov 1: 487-495, 2011.
77 Clinicaltrials.gov, NCT01799278. Results first posted in 2017.
78 Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A,
Halmos G, Kanashiro CA, Corey E and Vessella R: Targeted
chemotherapy with cytotoxic bombesin analogue AN-215
inhibits growth of experimental human prostate cancers. Int J
Cancer 118: 222-229, 2006.
79 Dizeyi N, Bjartell A, Hedlund P, Taskén KA, Gadaleanu V and
Abrahamsson PA: Expression of serotonin receptors 2B and 4
in human prostate cancer tissue and effects of their antagonists
on prostate cancer cell lines. Eur Urol 47(6): 895-900, 2005.
80 Nelson PS: Molecular States Underlying Androgen Receptor
Activation: A Framework for Therapeutics Targeting Androgen
Signaling in Prostate Cancer. J Clin Oncol 30: 644-646, 2012.
81 Ghannoum JE, DeLellis RA and Shin SJ: Primary carcinoid
tumor of the prostate with concurrent adenocarcinoma: a case
report. Int J Surg Pathol 12: 167-170, 2004.
82 Tash JA, Reuter VE and Russo P: Metastatic carcinoid tumor
of the prostate. J Urol 167: 2526-2527, 2002.
83 Reyes A and Moran CA: Low-grade neuroendocrine carcinoma
(carcinoid tumor) of the prostate. Arch Pathol Lab Med
128(12): e166-168, 2004.
84 Palmgren JS, Karavadia SS and Wakefield MR: Unusual and
underappreciated: small cell carcinoma of the prostate. Semin
Oncol 34: 22-29, 2007.
85 Kawai S, Hiroshima K, Tsukamoto Y, Tobe T, Suzuki H, Ito H,
Ohwada H and Ito H: Small cell carcinoma of the prostate
expressing prostate-specific antigen and showing syndrome of
inappropriate secretion of antidiuretic hormone: an autopsy case
report. Pathol Int 53: 892-896, 2003.
86 Rueda-Camino JA, Losada-Vila B, De Ancos-Aracil CL,
Rodríguez-Lajusticia L, Tardío JC and Zapatero-Gaviria A:
Small cell carcinoma of the prostate presenting with Cushing
Syndrome. A narrative review of an uncommon condition. Ann
Med 48(4): 293-299, 2016.
87 Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA,
Hitzhusen K, Millikan RE and Pisters LL: Prostate cancer
progression in the presence of undetectable or low serum
prostate-specific antigen level. Cancer 109: 198-204, 2007.
88 Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI,
Mosquera JM, Rubin MA and Nanus DM: Challenges in
recognizing treatment-related neuroendocrine prostate cancer. J
Clin Oncol 30: e386-389, 2012.
89 Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, Liu Z, Tan
D, Cheng L, Hatem F, Huang J and Anthony di Sant'Agnese P:
Small cell carcinoma of the prostate: an immunohistochemical
study. Am J Surg Pathol 30: 705712, 2006.
90 Wang W and Epstein JI: Small cell carcinoma of the prostate.
A morphologic and immunohistochemical study of 95 cases.
Am J Surg Pathol 32: 65-71, 2008.
Pósfai et al: Neuroendocrine Neoplasms of the Genitourinary Tract (Review)
3253
91 Simon RA, di Sant’Agnese PA, Huang LS, Xu H, Yao JL, Yang
Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei
J and Huang J: CD44 expression is a feature of prostatic small
cell carcinoma and distinguishes it from its mimickers. Hum
Pathol 40: 252-258, 2009.
92 Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso
P and Czerniak BA: TMPRSS2-ERG gene fusion in small cell
carcinoma of the prostate. Hum Pathol 42: 11-17, 2011.
93 Deorah S, Rao MB, Raman R, Raman R, Gaitonde K and
Donovan JF: Survival of patients with small cell carcinoma of
the prostate during 1973-2003: a population-based study. BJU
Int 109(6): 824-830, 2012.
94 Campedel L, Kossaï M, Blanc-Durand P, Rouprêt M, Seisen T,
Compérat E, Spano JP and Malouf G: Neuroendocrine prostate
cancer: Natural history, molecular features, therapeutic
management and future directions. Bull Cancer 104(9): 789-
799, 2017.
95 Evans AJ, Humphrey PA, Belani J, van der Kwast TH and Srigley
JR: Large cell neuroendocrine carcinoma of prostate: a
clinicopathologic summary of 7 cases of a rare manifestation of
advanced prostate cancer. Am J Surg Pathol 30: 684-693, 2006.
96 Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis
A and Lambou T: A combination therapy of dexamethasone and
somatostatin analog reintroduces objective clinical responses to
LHRH analog in androgen ablation-refractory prostate cancer
patients. J Clin Endocrinol Metab 86: 5729-5736, 2001.
97 Di Silverio F and Sciarra A: Combination therapy of
ethinylestradiol and somatostatin analogue reintroduces
objective clinical responses and decreases chromogranin a in
patients with androgen ablation refractory prostate cancer. J
Urol 170: 1812-1816, 2003.
98 Inoue S, Oka K, Araki T, Yano A, Tacho T, Fujii M, Kimoto K,
Murakami M and Ohshiro Y: Neuroendocrine carcinoma of the
prostate effectively treated by cisplatin and irinotecan – a case
report. Gan To Kagaku Ryoho 34(8): 1323-1325, 2007.
99 Garcia JA and Danielpour D: Mammalian target of rapamycin
inhibition as a therapeutic strategy in the management of
urologic malignancies. Mol Cancer Ther 7(6): 1347-1354, 2008.
100 Maebayashi T, Abe K, Aizawa T, Sakaguchi M, Ishibash N,
Fukushima S, Honma T, Kusumi Y, Matsui T and Kawata N:
Solitary pulmonary metastasis from prostate cancer with
neuroendocrine differentiation: a case report and review of relevant
cases from the literature. World J Surg Oncol 13: 173, 2015.
101 Wei J, Zheng X, Li L , Wei W, Long Z and He L: Rapid
progression of mixed neuroendocrine carcinoma-acinar
adenocarcinoma of the prostate: A case report. Oncol Lett
12(2): 1019-1022, 2016. 
102 Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang J, Kim
JK, Lee E, Wang Y, Chung JS, Gursky AM, Krebsbach PH,
Pienta KJ, Morgan TM and Taichman RS: CXCL12γ promotes
development of metastatic castration resistant prostate cancer
by induction of cancer stem cell and neuroendocrine
phenotypes. Cancer Res 78(8): 2026-2039, 2018.
103 Schneider A, Kollias A, Woziwodzki J and Stauch G: Testicular
metastasis of a metachronous small cell neuroendocrinic prostate
cancer after anti-hormonal therapy of a prostatic adenocarcinoma.
Case report and literature review. Urologe A 45(1): 75-80, 2006.
104 Benchekroun A, Nouini Y, Zannoud M, Kasmaoui el H, Jira M
and Iken A: Small cell carcinoma of the prostate: a case report
Ann Urol (Paris) 36(5): 314-317, 2002.
105 Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC,
Meirovitz A, Zouhair A, Freixa SV, Poortmans PH, Ash R and
Kuten A: Small cell (neuroendocrine) carcinoma of the prostate:
etiology, diagnosis, prognosis, and therapeutic implications--a
retrospective study of 30 patients from the rare cancer network.
Am J Med Sci 336(6): 478-488, 2008.
106 Spieth ME, Lin YG and Nguyen TT: Diagnosing and treating
small-cell carcinomas of prostatic origin. Clin Nucl Med 27(1):
11-17, 2002.
107 Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes
A, Troncoso P and Logothetis CJ: Results of a phase II study
with doxorubicin, etoposide, and cisplatin in patients with fully
characterized small-cell carcinoma of the prostate. J Clin Oncol
20(14): 3072-3080, 2002.
108 Berry W, Dakhil S, Modiano M, Gregurich M and Asmar L:
Phase III study of mitoxantrone plus low dose prednisone
versus low dose prednisone alone in patients with asymptomatic
hormone refractory prostate cancer. J Urol 168: 2439-2443,
2002.
109 Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V and
Pandha H: Low dose metronomic oral cyclophosphamide for
hormone resistant prostate cancer: a phase II study. J Urol 177:
2136-2140, 2007.
110 Yashi M, Terauchi F, Nukui A, Ochi M, Yuzawa M, Hara Y and
Morita T: Small-cell neuroendocrine carcinoma as a variant
form of prostate cancer recurrence: a case report and short
literature review. Urol Oncol 24(4): 313-317, 2006.
111 Uemura KI, Nakagawa G, Chikui K, Moriya F, Nakiri M, Hayashi
T, Suekane S and Matsuoka K: A useful treatment for patients with
advanced mixed-type small cell neuroendocrine carcinoma of the
prostate: A case report. Oncol Lett 5(3): 793-796, 2013.
112 Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM,
Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ,
Mathew P, Arap W, Troncoso P, Thall PF and Logothetis CJ:
Platinum-based chemotherapy for variant castrate-resistant
prostate cancer. Clin Cancer Res 19: 3621-3630, 2013.
113 Aparicio A and Tzelepi V: Neuroendocrine (small-cell)
carcinomas: why they teach us essential lessons about prostate
cancer. Oncology (Williston Park) 28(10): 831-838, 2014.
114 Peverelli G and Grassi P: Pure small cell recurrent prostate
cancer developing syndrome of inappropriate antidiuretic
hormone secretion. Tumori 103: e56-e59, 2017.
115 Akamatsu S, Inoue T, Ogawa O and Gleave ME: Clinical and
molecular features of treatment related neuroendocrine prostate
cancer. Int J Urol, 2018. doi: 10.1111/iju.13526. [Epub ahead
of print]
116 Okoye E, Choi EK, Divatia M, Miles BJ, Ayala AG and Ro JY:
De novo large cell neuroendocrine carcinoma of the prostate
gland with pelvic lymph node metastasis: a case report with
review of literature. Int J Clin Exp Pathol 7(12): 9061-9066, 2014.
117 Sun F, Zhang ZW, Tan EM, Lim ZLR, Li Y, Wang XC, Chua
SE, Li J, Cheung E and Yong EL: Icaritin suppresses
development of neuroendocrine differentiation of prostate cancer
through inhibition of IL-6/STAT3 and Aurora kinase A pathways
in TRAMP mice. Carcinogenesis 37(7): 701-711, 2016.
Received March 19, 2018
Revised April 17, 2018
Accepted April 18, 2018
ANTICANCER RESEARCH 38: 3243-3254 (2018)
3254
